Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06150703
Other study ID # APHP220667
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date February 2024
Est. completion date September 2027

Study information

Verified date July 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Maeliss Peigné, MCU-PH
Phone 01 48 02 68 56
Email maeliss.peigne@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).


Description:

It is currently established that obtaining a large number of oocytes is a key of success in IVF/ICSI cycles. However, it is also a risk factor for ovarian hyperstimulation syndrome (OHSS) and a risk factor of implantation failure after fresh embryo transfer because of the alteration of endometrial receptivity. A freeze all strategy can be proposed to avoid these risks but vitrification of embryos, although more efficient than slow freezing in terms of embryo survival, is not without risk. Furthermore, proper endometrial and embryo timing for frozen-thawed embryo transfer is still debated. Recent preliminary works suggest another possible way to combine an optimal ovarian response with the recovery of a large number of oocytes, good chances of implantation and a reduced risk of OHSS. To achieve this goal, ovulation triggering and luteal phase support need to be modified together. The human chorionic gonadotropin (hCG) (mimicking the Luteinising Hormone (LH)peak to trigger ovulation) that induces OHSS is replaced by an a GnRH agonist (GnRHa) triggering allowing an endogenous peak of Follicle Stimulating Hormone (FSH) and LH. Then, the usual support of the luteal phase by exogenous vaginal progesterone, whose absorption seems to be suboptimal for about 30% of patients, is replaced by endogenous progesterone production by the corpora lutea, supported by the maintenance of LH activity through the continuation of agonist of gonadotropin releasing hormone (AgoGnRH) in the luteal phase. Pilot studies show that a 10% to 15% increase in ongoing pregnancy rates can be expected with this type of protocol. The objective of our study is to demonstrate an increase in ongoing pregnancy rate per cycle with this new strategy combining GnRHa triggering and GnRHa luteal phase support compared to the reference protocol (hCG triggering and exogenous progesterone luteal phase support).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 652
Est. completion date September 2027
Est. primary completion date September 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: - Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law. - Patients aged 18 to 39 included - First or second attempt of IVF or ICSI - BMI < 35 kg/m2 - Anti-Mullerian hormone (AMH) > 1 ng/ml (= 7 pmol/L) and/or antral follicle count = 8 - AMH < 5 ng/ml and/or antral follicle count <40 - Treatment with recombinant FSH - Antagonist protocol (with pre-treatment or not) - Initial dose of recombinant FSH between 75 and 450 IU - Signed informed consent - Affiliation to the social security system (excluding AME) Exclusion Criteria: - Patient or partner with HIV, hepatitis B virus (HBV) or Hepatitis C Virus (HCV) - ICSI with sperm from testicular biopsy - Pre-implantation diagnosis - Hypogonadotropic hypogonadism (amenorrhea or spaniomenorrhea with basal LH <1.2 IU/L) - History of severe ovarian hyperstimulation syndrome (OHSS) - Unoperated hydrosalpinx - Intracavitary polyps or myomas deforming the cavity - Known hypersensitivity to the investigational drugs and/or their excipients (human chorionic gonadotropin, progesterone, nafarelin acetate, GnRH, GnRH analogues, mannitol, sodium chloride, water for injection, glacial acetic acid, Sodium hydroxide and/or hydrochloric acid, sorbitol, purified water, benzalkonium chloride, sunflower oil, soybean lecithin, gelatin, glycerol, titanium dioxide (E171), methionine, poloxamer 18, phosphoric acid). - Gynaecological bleeding or genital haemorrhage - Tumours of the hypothalamus or pituitary gland - Ovarian enlargement or cysts unrelated to polycystic ovary syndrome - Severe adenomyosis requiring a long protocol - Carcinoma of the ovary, uterus or breast - Active thromboembolic events - Severe impairment of liver function - Breastfeeding women - Patients under court protection, guardianship or curators - Current participation in another therapeutic interventional trial on the day of inclusion - Patients who do not speak or understand French

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ovulation induction with hCG + Luteal phase support with vaginal progesterone
hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test

Locations

Country Name City State
France Maeliss Peigné Bondy

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth, defined as the presence of a live birth after 22 weeks' gestation. Twin pregnancies will be counted as a single birth. To demonstrate an increase in the rate of live births after 22 weeks' amenorrhoea (SA) per cycle with induction and support by GnRH agonist compared with the reference protocol combining induction by hCG and luteal support by exogenous vaginal progesterone 22 weeks' gestation
Secondary Embryo implantation defined as the presence of a gestational sac on the first ultrasound (5-8 WG) Demonstrate improvement of embryo implantation rates with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5-8 weeks' gestation
Secondary Pregnancy defined as an hCG level > 10 IU/ml 14 days after oocyte retrieval. Demonstrate an improvement in pregnancy rate with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 14 days after oocyte retrieval.
Secondary Clinical pregnancy, defined as an intrauterine gestational sac with embryo showing cardiac activity on ultrasound at 5-10 WG Demonstrate an improvement in clinical pregnancy rate with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5-10 weeks' gestation
Secondary Miscarriage prior to 12 WG, defined as the termination of a pregnancy prior to 12 WG. Demonstrate a decrease in the rate of miscarriage per pregnancy with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 12 weeks' gestation
Secondary Ongoing pregnancy, defined as the presence of an intra-uterine sac with an embryo with cardiac activity visible on ultrasound between 11 weeks of gestations(WG) and 13 WG+6 days (first trimester ultrasound). Demonstrate an increase ongoing pregnancy rate at 12 weeks of gestation (12 WG) per cycle with GnRHa triggering and GnRHa luteal phase support compared with the reference protocol: hCG triggering and exogenous vaginal progesterone luteal phase support. first trimester ultrasound (11 weeks of gestation and 13weeks of gestation +6days)
Secondary Number of patients with gravidic hypertension and its onset, Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with pre-eclampsia and its onset, Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with gestational diabetes and its onset Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with term and mode of delivery Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with medical termination of pregnancy Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with late miscarriage (between 12 and 22 WG) Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Number of patients with fetal death in utero Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. between 12 weeks of gestation and 22 weeks of gestation
Secondary Ovarian hyperstimulation syndrome, defined as the presence of moderate to severe syndrome, early and late. Early defined as the period before D10 post retrieval and late defined as pregnancy related OHSS, after D10 post oocyte retrieval Demonstrate a decrease in the rate of moderate to severe and early and late OHSS with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. before Day 10 post retrieval and after Day 10 post oocyte retrieval
Secondary Progesterone levels on day of oocyte pick up and at Day 7 post oocyte pick up. Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. Day 7 post oocyte pick up
Secondary Estradiol levels on day of oocyte pick up and at Day 7 post oocyte pick up. Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. Day 7 post oocyte pick up
Secondary LH levels on day of oocyte pick up and at Day 7 post oocyte pick up. Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. Day 7 post oocyte pick up
Secondary hCG levels on day of oocyte pick up and at Day 7 post oocyte pick up. Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. Day 7 post oocyte pick up
Secondary Progesterone levels during follow-up, presence of pregnancy and presence of miscarriage. Assess the association of progesterone levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 19 months
Secondary Estradiol levels during follow-up, presence of pregnancy and presence of miscarriage. Assess the association of estradiol levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 19 months
Secondary LH levels during follow-up, presence of pregnancy and presence of miscarriage. Assess the association of LH levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 19 months
Secondary hCG levels during follow-up, presence of pregnancy and presence of miscarriage. Assess the association of hCG levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 19 months
Secondary All adverse events up to delivery Evaluate the side effects with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 19 months
Secondary Number of oocytes collected, Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. oocyte puncture visit
Secondary number of mature oocytes Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. oocyte puncture visit
Secondary number of oocytes fertilised, Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5th day post oocyte puncture visit
Secondary number of embryos on the second day of development, Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5th day post oocyte puncture visit
Secondary number of blastocysts obtained, Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5th day post oocyte puncture visit
Secondary number of blastocysts transferred, Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5th day post oocyte puncture visit
Secondary number of blastocysts frozen. Compare embryonic development with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support. 5th day post oocyte puncture visit
See also
  Status Clinical Trial Phase
Completed NCT00696878 - Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) Phase 3
Recruiting NCT04122729 - N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
Not yet recruiting NCT02534857 - A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment N/A
Recruiting NCT01406600 - Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles N/A
Completed NCT01406028 - Does Emotional Support Decrease In Vitro Fertilization Stress? N/A
Withdrawn NCT00541892 - Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine Phase 2
Completed NCT00708383 - in Vitro Fertilization (IVF) Media Protein and Live Birth Rates N/A
Completed NCT03627533 - The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF N/A
Recruiting NCT04160611 - What Amount of Stress is Enough for a Successful Conception? Phase 3
Suspended NCT01600794 - To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization N/A
Completed NCT01507376 - Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity Phase 3
Terminated NCT00866008 - A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) Phase 4
Recruiting NCT04082650 - Vitamin D and Pregnancy Outcome in PCOS Patients N/A
Recruiting NCT03758833 - eSET or eDET Associated to PGT in IVF N/A
Not yet recruiting NCT04407871 - Acupuncture and Chinese Herbal Medicine to Improve Live Birth Rate of in Vitro Fertilization (IVFAct) N/A
Recruiting NCT03345030 - The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome N/A
Not yet recruiting NCT06367985 - CAPA-IVM Culture With Low Oxygen Tension N/A
Not yet recruiting NCT03090438 - IVF Outcomes After Varicocele Repair N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Completed NCT01343992 - Bed Rest or no Bed Rest? N/A